Nootropics Index - Save on smarter supplements
Nootropics>Peptides, proteins & enzymes>Selank
Peptides, proteins & enzymes

Selank

Selank

Selank is a synthetic tuftsin-analog peptide studied mainly in small Russian patient studies. Healthy-adult focus or memory benefits and an oral supplement dose are not established. Compare nasal drops and research vials by identity, route and verified peptide amount; their prices and evidence are not interchangeable.

CalmRelaxationStress ResilienceGabaergicSyntheticClinical ResearchLimited Human Evidence
Updated October 2026/6 min read/9 citations
Reviewed by the NootropicsIndex editorial team.Method: prioritize cited human research and official safety or regulatory sources; compare retailer-listed prices without endorsing products.Affiliate disclosure
01

What is it?

Synthetic tuftsin-derived peptide

2

Selank is a synthetic heptapeptide with sequence TKPRPGP, described as a tuftsin analog. This page covers the parent peptide; acetate/diacetate salts and N-acetyl derivatives need distinct identity checks.

Evidence is narrower than marketing3
The human evidence comes mainly from small Russian anxiety-spectrum patient studies. It does not establish a healthy-adult focus or memory benefit, an oral supplement regimen, or equivalence between nasal drops and research vials.

What the human studies measured

3

A 62-patient study compared Selank with medazepam using anxiety scales; a separate 60-patient study compared it with phenazepam. The reports concern selected patients, not healthy adults, and the indexed abstracts do not provide dose details or robust adverse-event rates.

02

Names, aliases and forms

Common NameSelank
Spelling VariantSelanc
Research CodeTP-7
03

Mechanisms of action

GABA and peptide-system signals

5

Animal-derived membrane experiments found concentration-dependent GABA-binding modulation and non-additive effects with diazepam and olanzapine. These laboratory results do not establish a human cognitive benefit or clinical interaction rate.

04

Potential effects and evidence map

Two small Russian comparator studies in anxiety-spectrum patients reported signals, but neither establishes a benefit magnitude for healthy adults. Laboratory GABA findings and rat experiments provide mechanism context, not proof of cognitive enhancement or clinical interaction safety.

Effect domainMagnitudeGrade
Calm / relaxation3
UnknownConfidence: Low

Small patient comparator studies report anxiety-related findings, but no healthy-adult calm or relaxation magnitude is established.

Note Grade C describes the limited patient evidence. Zero denotes no established healthy-adult magnitude, not demonstrated ineffectiveness.

0/5
C
Memory / learning3
UnknownConfidence: Low

A healthy-adult memory or learning benefit is not established by the cited patient studies.

Note Zero denotes no established healthy-adult benefit magnitude here, not demonstrated ineffectiveness. Patient signals and limitations are described in the evidence summary.

0/5
E
05

Typical dosages and timing

Russian label per administration82 drops per nostril

The manufacturer-hosted Russian instructions specify three administrations daily for the Selank diacetate 0.15% nasal product. This describes that product only, not an oral, spray-pump or injection regimen.

Nasal-product concentration81.5 mg/mL

The Russian label identifies Selank diacetate at this concentration. It cannot be converted reliably into micrograms per spray or drop without the actual delivery volume. Bottle mass alone does not establish exposure.

06

Timing & effect horizon

Effect horizonUnknown
Unknown
Label course8

The Russian nasal-product label describes a 14-day course. It is product-label context, not effect duration.

Repeated courses8

The same label discusses repetition after medical consultation. Repeated research-peptide cycles have no established safe schedule in the cited human evidence.

Onset and duration are uncertain4

A 60-patient comparator abstract reported anxiety findings one week after the last administration. It does not establish single-dose duration or healthy-user onset, and gives no dose or course duration.

07

Safety, side effects and risk profile

Compounded-peptide concern9
FDA flags possible immunogenicity from aggregation and peptide-related impurities for certain routes of compounded Selank acetate. Human safety information remains incomplete.
Oral risk scale does not apply9
The cited evidence concerns intranasal patient use and laboratory research, not an established healthy-adult oral supplement regimen. An oral base-risk score therefore does not apply. This is not a safety assurance; route-specific compounded-peptide concerns remain relevant.
Legal / regulatory risk9
Confidence: High

U.S. compounding status requires separate review from product identity.

Note As of 2026-10-19, the FDA source lists Selank acetate in withdrawn nominations. This is U.S. compounding context, not a global legal rule.

Unscored
A
Evidence uncertainty3
Confidence: High

Healthy-adult oral safety and long-term repeated-use risk cannot be estimated.

Note Small patient reports cannot establish rare-event frequency or safety across routes.

Unscored
C
Interaction risk5
Confidence: Low

Laboratory interaction findings have no established human risk magnitude.

Note GABA-binding experiments with diazepam and olanzapine do not establish a clinical contraindication or a safe combination.

Unscored
D
Pregnancy / lactation caution8
Confidence: High

The Russian nasal-product label excludes pregnancy, breastfeeding and under-18 use.

Note These are label-specific cautions; adequate safety studies are absent.

Unscored
E
Label tolerability and excluded groups8

The nasal-product instructions mention unpleasant taste and allergic reactions, and exclude pregnancy, breastfeeding and use under 18. They do not provide a reliable adverse-event frequency estimate.

08

Interactions and cautions

Human interaction uncertainty5

Laboratory GABA-binding results involving diazepam and olanzapine differ from clinical interaction evidence. They neither prove a dangerous combination nor establish that stacking Selank with CNS-active drugs or alcohol is safe.

09

Legal and regulatory status

U.S. compounded-drug context9

As of October 2026, FDA lists Selank acetate among withdrawn bulk-substance nominations and flags possible route-dependent immunogenicity with incomplete human safety information. This compounding entry is not a product approval or a worldwide legal ruling.

Russian nasal-drug context8

As reviewed in 2026, Peptogen hosts Russian instructions for Selank nasal drops. A Russian product label does not confer FDA approval or establish lawful import, compounding or sale in another jurisdiction.

10

Practical buying and quality notes

  • Compare parent Selank separately from N-acetyl analogs, and check the declared salt and net peptide amount. A purity percentage alone does not resolve peptide identity or route-specific impurity concerns.9
  • Compare nasal solutions by verified concentration and usable volume, and vials by verified peptide mass and vial count. A missing or zero catalog amount is not a free product or a trustworthy price-per-gram denominator; verify the merchant package before comparing.8
11

FAQ

What is Selank?

2

Selank is a synthetic seven-amino-acid peptide, also written Selanc or TP-7. Its parent sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro; modified analogs should be checked separately.

What is the Selank dosage?

8

No oral supplement dose is established by the cited evidence. Nasal-product label details appear in the dosage section; they do not establish doses for research vials or other delivery devices.

How long is a Selank course?

8

The label course appears above. It should not be read as a recommended cycle for an online peptide product; long-term safety and repeat-course schedules remain uncertain.

Does Selank improve focus or memory?

3

The cited small patient studies do not establish a healthy-user focus or memory benefit. Anxiety-related study findings cannot supply a reliable cognitive-enhancement magnitude.

Is Selank legal to buy?

9

As of October 2026, the U.S. FDA compounding source and the Russian nasal-product label describe different regulatory contexts. Research-only availability does not establish permission for human use or import in the buyer's country.

12

References

  1. FDA GSRS. SELANK substance identity record. Accessed 2026-10-19.
  2. PubChem. Selank (CID 11765600). Accessed 2026-10-19.
  3. Zozulia AA, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48.
  4. Medvedev VE, et al. A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders. Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(7):17-22.
  5. Vyunova TV, Andreeva L, Shevchenko K, Myasoedov N. Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein Pept Lett. 2018;25(10):914-923.
  6. Kasian A, et al. Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats. Behav Neurol. 2017;2017:5091027.
  7. Development of Peptide Biopharmaceuticals in Russia. Pharmaceutics. 2022;14(4):716.
  8. Peptogen. Selank 0.15% nasal drops: Russian medical-use instructions hosted by the manufacturer. Accessed 2026-10-19.
  9. U.S. FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks: Selank acetate (TP-7). Accessed 2026-10-19.
Note

This page is informational and summarizes available evidence. It is not medical advice, a recommendation, or a substitute for guidance from a qualified clinician.